1. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
- Author
-
Daniel Catovsky, Matthew C.H. Ng, A C Wotherspoon, David Cunningham, Mark A. Hill, Alan Horwich, Ian Chau, A. R. Norman, and Justin S. Waters
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Lymphoma ,medicine.drug_class ,cisplatin ,Salvage therapy ,Neutropenia ,Deoxycytidine ,Methylprednisolone ,Antimetabolite ,Gastroenterology ,Refractory ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Clinical Studies ,medicine ,Humans ,Aged ,Salvage Therapy ,Nucleoside analogue ,business.industry ,gemcitabine ,Middle Aged ,medicine.disease ,Survival Analysis ,Gemcitabine ,Surgery ,relapsed ,refractory ,Regimen ,Treatment Outcome ,Oncology ,Drug Resistance, Neoplasm ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma. The best-achieved response rate (RR) was 79% (95% CI 64–91), with a complete RR of 21%. In patients with chemo-resistant disease, the RR was 63%. Myelosuppression was the main toxicity, the incidence of Grade 3 or 4 anaemia, neutropenia and thrombocytopenia was 17.1, 61.0 and 53.7% respectively. Only one patient had neutropenic sepsis and none of the patients suffered from haemorrhage. Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation. more...
- Published
- 2005
- Full Text
- View/download PDF